The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat

  title={The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat},
  author={John F. Cryan and Anna M Redmond and John P Kelly and Brian E. Leonard},
  journal={European Neuropsychopharmacology},

Chronic Administration of 5-HT1A Receptor Agonist Relieves Depression and Depression-Induced Hypoalgesia

It is demonstrated that chronic administration of 8-OH-DPAT reversed the depression-induced decrease in pain sensitivity in rats, suggesting that 5-HT1A receptor may play a role in the Depression-associated hypoalgesia.

The role of serotonin receptor subtypes in treating depression: a review of animal studies

The involvement of 5- HT receptors in the antidepressant-like effects of SSRIs is complex and involves the orchestration of stimulation and blockade at different 5-HT receptor subtypes.

Association of 5-HT1A Receptors with Affective Disorders

The purpose of this chapter is to analyze and discuss the current information about 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5- HT 1A-R, in addition to their expression and pharmacology that are important to treat- ment of affective disorders symptoms.

5‐HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response

It is concluded that selective targeting of 5‐HT receptors may lead to a faster acting and more efficient antidepressant response.



Anticonflict effects of the 5-HT1A compound flesinoxan

It would appear that flesinoxan should be a useful compound in the clinical management of anxiety after being examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT 1A receptor subtype.

Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature

Flesinoxan is a highly potent and selective 5‐HT1A full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major

An open study of oral flesinoxan, a 5‐HT1A receptor agonist, in treatment‐resistant depression

The observations suggested that flesinoxan is an antidepressant agent and that it may be of particular value in some difficult, treatment-resistant depressions.

Further Characterization of the Discriminative Stimulus Induced by Flesinoxan

The present results are in favour of a 5-HT1A mechanism for the discriminative stimulus of flesinoxan and consistent with the results of previous drug discrimination studies with fles inoxan.

The effect of BIMT 17, a new potential antidepressant, in the forced swimming test in mice

Neither the reduction of 5-HT synthesis brought about by p-chlorophenylalanine nor the selective destruction of5-HT containing neurons by 5,7-dihydroxytryptamine reduced the BIMT 17 effect, suggesting that BIMM 17 acts postsynaptically in increasing struggling behaviour.